Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2025.1751999 Correction Correction: Case Report: The integration of chemoradiotherapy and immunotherapy in a patient with advanced-stage renal squamous cell carcinoma and pulmonary metastases NiuYanlin 1 † Writing – original draft Writing – review & editing WangShengchao 1 2 † Data curation Writing – review & editing DengXinzhou 1 2 Writing – review & editing LuoMing 1 2 * Writing – review & editing ChaiJingjing 1 2 * Writing – review & editing LuoZhiguo 1 2 * Writing – review & editing Department of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study, Shiyan, Hubei, China Correspondence: Ming Luo, heavry@126.com; Jingjing Chai, chaijingjing@hbmu.edu.cn; Zhiguo Luo, luozhiguo@hbmu.edu.cn

These authors have contributed equally to this work

 28 11 2025 2025 16 1751999 22 11 2025 24 11 2025 Copyright © 2025 Niu, Wang, Deng, Luo, Chai and Luo. 2025 Niu, Wang, Deng, Luo, Chai and Luo https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Case Report: The integration of chemoradiotherapy and immunotherapy in a patient with advanced-stage renal squamous cell carcinoma and pulmonary metastases By Niu Y, Wang S, Deng X, Luo M, Chai J and Luo Z (2025) Front. Immunol. 16:1645909. doi: 10.3389/fimmu.2025.1645909 renal squamous cell carcinoma pulmonary metastases immunotherapy radiotherapy chemotherapy Hubei Provincial Central Guidance Local Science and Technology Development Project 10.13039/501100019034 Grant No.2022BGE270  项目编号 2022BGE270 Natural Science Foundation of Hubei Province 10.13039/501100003819 2024AFB335, 2024AFB352, 2024AFD434, 2023AFB180 section-at-acceptance Cancer Immunity and Immunotherapy

“Affiliation 1: Department of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China” was omitted from the paper. This affiliation has now been added for author(s) Shengchao Wang.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland